COGT Earnings Preview

FDA approval imminent, analyst lifts target 33%

This is a pre-revenue biotech at an inflection point. The analyst upgrade is not hype—it's a direct response to derisk: regulatory approval removes the clinical credibility question, and the cash position covers multiple launches without equity dilution. A green light on bezuclastinib proves Cogent can execute on clinical development AND transition to commercialization, a test most pre-launch biotech companies fail.

Watch: FDA approval decision within weeks is the near-term gate. Watch for the April 2026 GIST NDA submission to confirm pipeline momentum—two approved assets would materially shift the narrative from "clinical promise" to "commercial execution risk." Revenue visibility is still years away, but approval unlocks that timeline.